Astraveus Highlights Lakhesys Prototype Efficiency in CAR-T Manufacturing Evaluations

According to a recent LinkedIn post from Astraveus, the company recently hosted representatives from Institut Paoli-Calmettes at its Paris facility to evaluate its Lakhesys microfluidic cell therapy platform. The post highlights head-to-head comparison runs between Lakhesys and an unnamed industry benchmark, focusing on transduction efficiency in lentiviral-based cell manufacturing.

The LinkedIn update suggests that Lakhesys achieved roughly 2.5x higher transduction efficiency than the benchmark control while using low-volume lentiviral delivery and without adding extra reagents. Early feedback from the external partners, described as experienced cell therapy manufacturing leaders, is characterized in the post as supportive of Lakhesys as a potential innovation in CAR-T and point-of-care production.

For investors, if such efficiency gains are validated at scale, they could translate into lower reagent costs, improved yields, and potentially more competitive economics for decentralized cell therapy manufacturing. This may position Astraveus as a differentiated technology provider in the CAR-T and cell therapy tools market, where efficiency, cost, and scalability are key drivers of adoption.

The emphasis on a new two-unit functional prototype also indicates that Astraveus appears to be progressing along its product development roadmap, moving from concept toward more mature hardware suitable for external evaluations. Ongoing evaluation programs with additional partners, as mentioned in the post, could help build a broader data set and reference base, which would be important for future commercialization and partnership discussions.

More broadly, the focus on microfluidics for CAR-T manufacturing aligns Astraveus with industry trends toward automation, process intensification, and point-of-care production. If the platform ultimately proves robust and compliant with regulatory and GMP requirements, it could enhance the company’s strategic value to biopharma manufacturers and potentially support future funding or strategic transaction opportunities.